A detailed history of Bank Of America Corp transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Bank Of America Corp holds 2,497,940 shares of ADCT stock, worth $5.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,497,940
Previous 1,216,418 105.35%
Holding current value
$5.07 Million
Previous $3.84 Million 104.74%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.59 - $4.01 $3.32 Million - $5.14 Million
1,281,522 Added 105.35%
2,497,940 $7.87 Million
Q2 2024

Aug 14, 2024

BUY
$2.55 - $5.09 $57,556 - $114,886
22,571 Added 1.89%
1,216,418 $3.84 Million
Q1 2024

May 15, 2024

SELL
$1.66 - $5.29 $550,944 - $1.76 Million
-331,894 Reduced 21.75%
1,193,847 $5.36 Million
Q4 2023

Feb 14, 2024

SELL
$0.47 - $1.79 $66,256 - $252,338
-140,971 Reduced 8.46%
1,525,741 $2.53 Million
Q2 2023

Aug 14, 2023

BUY
$1.9 - $2.66 $41,617 - $58,264
21,904 Added 1.33%
1,666,712 $3.58 Million
Q1 2023

May 12, 2023

BUY
$1.92 - $5.45 $77,149 - $218,991
40,182 Added 2.5%
1,644,808 $3.21 Million
Q4 2022

Feb 10, 2023

BUY
$2.87 - $5.24 $4.59 Million - $8.37 Million
1,597,765 Added 23287.64%
1,604,626 $6.16 Million
Q3 2022

Nov 14, 2022

BUY
$4.66 - $10.31 $2,418 - $5,350
519 Added 8.18%
6,861 $33,000
Q2 2022

Aug 12, 2022

SELL
$5.96 - $14.99 $7,551 - $18,992
-1,267 Reduced 16.65%
6,342 $50,000
Q1 2022

May 16, 2022

SELL
$13.28 - $20.03 $1.24 Million - $1.87 Million
-93,268 Reduced 92.46%
7,609 $112,000
Q4 2021

Feb 08, 2022

BUY
$19.29 - $31.51 $1.79 Million - $2.92 Million
92,621 Added 1121.86%
100,877 $2.04 Million
Q3 2021

Nov 15, 2021

SELL
$20.45 - $30.0 $33,333 - $48,900
-1,630 Reduced 16.49%
8,256 $225,000
Q2 2021

Sep 13, 2021

BUY
$20.38 - $27.04 $201,476 - $267,317
9,886 New
9,886 $240,000

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $158M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.